“A number of key personnel who work for JOINN Biologics and its parent company studied or worked at the Academy of Military Medical Sciences in Beijing.

Source: https://www.lewrockwell.com/2023/05/joseph-mercola/lab-grown-meat-is-25-times-worse-for-the-environment/

Biologics are a fast-growing class of medicines and only fifth of patients who are eligible for biologic medicine are currently receiving one.

Source: https://seekingalpha.com/article/4597366-astrazeneca-plc-azn-q1-2023-earnings-call-transcript?source=feed_all_articles

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, underlined the importance of vaccination in protecting against severe COVID-19 consequences.

Source: https://sacobserver.com/2023/09/fda-approves-updated-covid-19-vaccines-amid-rising-cases-and-hospitalizations/

Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in ADMA Biologics by 0.4% during the 1st quarter.

Source: https://www.americanbankingnews.com/2023/05/19/adma-biologics-nasdaqadma-coverage-initiated-by-analysts-at-stocknews-com.html

Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $34.00 price objective on shares of AbCellera Biologics in a research report on Wednesday, February 22nd.

Source: https://www.etfdailynews.com/2023/05/27/belpointe-asset-management-llc-acquires-new-stake-in-abcellera-biologics-inc-nasdaqabcl/

IFP Advisors Inc acquired a new position in shares of AbCellera Biologics Inc. () in the third quarter, reports.

Source: https://www.etfdailynews.com/2023/02/19/ifp-advisors-inc-invests-64000-in-abcellera-biologics-inc-nasdaqabcl-2/

Key players profiled include AGC Biologics, Charles River Laboratories, Catalent, Danaher (Cytiva), Lonza, Merck KGaA, and others, contributing to the market's evolution.

Source: https://www.prnewswire.com/news-releases/unleashing-potential-aav-focused-cdmo-market-propelled-by-24-61-cagr-transforming-gene-therapies-301910077.html

Meanwhile, China’s CanSino Biologics Inc. has entered the “test production phase” for its COVID-19 mRNA booster vaccine, known as CS-2034, which targets new variants of the virus known as Omicron.

Source: https://www.voiceofsikkim.com/china-lifting-covid-19-restriction-after-3-years/

Robeco Institutional Asset Management B.V. purchased a new stake in ADMA Biologics in the fourth quarter valued at approximately $42,000.

Source: https://www.etfdailynews.com/2023/08/01/arizona-state-retirement-system-has-188000-stake-in-adma-biologics-inc-nasdaqadma/

SHANGHAI — China’s CanSino Biologics Inc has entered the “test production phase” for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday.

Source: https://newsinfo.inquirer.net/1713671/chinese-made-covid-19-mrna-vaccine-starts-trial-production

THOUSAND OAKS, Calif. /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.

Source: https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/FDA-Grants-Priority-Review-to-Amgen-s-Tarlatamab-Application-for-Advanced-Small-Cell-Lung-Cancer-45563652/?utm_medium=RSS&utm_content=20231213